Literature DB >> 17218847

Update on ovarian cancer screening.

Adnan Munkarah1, Madhumita Chatterjee, Michael A Tainsky.   

Abstract

PURPOSE OF REVIEW: Epithelial ovarian cancer is usually diagnosed in the advanced stage and carries a poor prognosis. When detected at an early stage, the 5-year survival rate is 90%. Despite the availability of various diagnostic tools for ovarian cancer screening, high levels of sensitivity and specificity are not achievable. There is therefore an ongoing need to identify new screening tests and strategies that should be readily available, relatively noninvasive, and achieve high sensitivity, specificity, and positive and negative predictive values. RECENT
FINDINGS: Our review focuses on various screening technologies including serum biomarkers, transvaginal ultrasonography as well as multimodality screening that can be used for early detection of ovarian cancer. The efficacy of different screening tools is discussed along with the efforts made to improve sensitivity, specificity and positive predictive value. The initial results of two large population-based screening studies are presented.
SUMMARY: An optimal screening test with high levels of sensitivity and specificity is indispensable for early detection of ovarian cancer. Serological screening with serum biomarkers (serum proteins and autoantibodies) can be used as a first-line screening test. In combination with TVS or color-flow Doppler imaging, this may prove very effective in early detection of ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17218847     DOI: 10.1097/GCO.0b013e328011ec99

Source DB:  PubMed          Journal:  Curr Opin Obstet Gynecol        ISSN: 1040-872X            Impact factor:   1.927


  13 in total

Review 1.  Protein biomarkers of ovarian cancer: the forest and the trees.

Authors:  Brian M Nolen; Anna E Lokshin
Journal:  Future Oncol       Date:  2012-01       Impact factor: 3.404

2.  Effects of salinomycin on human ovarian cancer cell line OV2008 are associated with modulating p38 MAPK.

Authors:  Bei Zhang; Xueya Wang; Fengfeng Cai; Weijie Chen; Uli Loesch; Johannes Bitzer; Xiao Yan Zhong
Journal:  Tumour Biol       Date:  2012-07-07

3.  Ovarian cancer screening and early detection in the general population.

Authors:  Jose A Rauh-Hain; Thomas C Krivak; Marcela G Del Carmen; Alexander B Olawaiye
Journal:  Rev Obstet Gynecol       Date:  2011

4.  Differential methylation profile of ovarian cancer in tissues and plasma.

Authors:  Anatoliy Melnikov; Denise Scholtens; Andrew Godwin; Victor Levenson
Journal:  J Mol Diagn       Date:  2008-12-12       Impact factor: 5.568

5.  Study of the molecular recognition of aptamers selected through ovarian cancer cell-SELEX.

Authors:  Dimitri Van Simaeys; Dalia López-Colón; Kwame Sefah; Rebecca Sutphen; Elizabeth Jimenez; Weihong Tan
Journal:  PLoS One       Date:  2010-11-01       Impact factor: 3.240

6.  Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule.

Authors:  Adam N Rosenthal; Lindsay Fraser; Ranjit Manchanda; Philip Badman; Susan Philpott; Jessica Mozersky; Richard Hadwin; Fay H Cafferty; Elizabeth Benjamin; Naveena Singh; D Gareth Evans; Diana M Eccles; Steven J Skates; James Mackay; Usha Menon; Ian J Jacobs
Journal:  J Clin Oncol       Date:  2012-12-03       Impact factor: 44.544

7.  Laparoscopic optical coherence tomography imaging of human ovarian cancer.

Authors:  Lida P Hariri; Garret T Bonnema; Kathy Schmidt; Amy M Winkler; Vrushali Korde; Kenneth D Hatch; John R Davis; Molly A Brewer; Jennifer K Barton
Journal:  Gynecol Oncol       Date:  2009-05-29       Impact factor: 5.482

8.  Quantitative multiparametric MRI of ovarian cancer.

Authors:  Jori S Carter; Joseph S Koopmeiners; Jessica E Kuehn-Hajder; Gregory J Metzger; Navneeth Lakkadi; Levi S Downs; Patrick J Bolan
Journal:  J Magn Reson Imaging       Date:  2013-04-04       Impact factor: 4.813

Review 9.  Aptamers from cell-based selection for bioanalytical applications.

Authors:  Weihong Tan; Michael J Donovan; Jianhui Jiang
Journal:  Chem Rev       Date:  2013-03-19       Impact factor: 60.622

10.  Risk-reducing surgery for ovarian cancer: outcomes in 300 surgeries suggest a low peritoneal primary risk.

Authors:  D Gareth R Evans; Richard Clayton; Paul Donnai; Andrew Shenton; Fiona Lalloo
Journal:  Eur J Hum Genet       Date:  2009-04-15       Impact factor: 4.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.